A Terminal Disclaimer Is Not an Escape Hatch
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Nefi R. Oliva & Nathan D. Reeves
Before Lourie, Dyk, and Reyna. Appeal from the Patent Trial and Appeal Board.
Summary: Obviousness-type double patenting analyses for patents with Patent Term Adjustments are based on the adjusted expiration date of the patent.
Cellect sued Samsung for infringement of four patents (the “challenged patents”) that claimed priority to the same parent application. Each of the challenged patents was granted Patent Term Adjustment (“PTA”) for USPTO delays during their prosecutions. Cellect did not file terminal disclaimers for any of the challenged patents. Samsung requested ex parte reexaminations, asserting that the challenged patents were unpatentable based on obviousness-type double patenting. The examiner agreed and invalidated the challenged claims because they were obvious variants of earlier-expiring claims in the same patent family.
Cellect appealed the rejection of the challenged claims to the Board. Cellect noted that obviousness-type double patenting does not invalidate a validly obtained Patent Term Extension (“PTE”) under 35 U.S.C. § 156 and argued that unpatentability of the challenged patents under a double-patenting analysis should be based on the expiration dates of the challenged patents before any PTA is added, similar to how PTE is handled. However, the Board held that the text of pre-AIA 35 U.S.C. § 154 makes clear that unlike PTE, PTA cannot adjust a term beyond the disclaimed date in any terminal disclaimer, and that double-patenting analyses should be based on the adjusted expiration date of the patent.
The Federal Circuit affirmed the Board’s decision. The Federal Circuit held that PTA and PTE should be treated differently when determining whether claims are unpatentable under obviousness-type double patenting, relying on differences between the two statutes. In particular, the Federal Circuit held that a double-patenting analysis is performed based on the expiration date of the patent after adding any PTA. The Court further explained that, because the patents had now expired, the opportunity for Cellect to file a terminal disclaimer had passed and that terminal disclaimers are not an escape hatch to be deployed after a patent expires.
Editor: Paul Stewart
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…